CRANFORD, N.J., Nov. 9,
2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the
"Company") (Nasdaq: CTXR), a specialty pharmaceutical company
developing and commercializing critical care drug products, today
announced that it will present at the H.C. Wainwright
6th Annual Israel Conference to be held virtually on
November 12, 2020. Myron Holubiak, Chief Executive Officer of
Citius, will provide an update of the Company's products under
development and provide an overview on Thursday, November 12, at 2:30 p.m. Eastern Time. Mr. Holubiak will also
conduct virtual one-on-one meetings with investors during the
conference.
Webcast:
https://journey.ct.events/view/43d1a83f-22aa-464f-a250-de8240b51195
The Company recently issued its October
2020 Letter to Shareholders, highlighting recent updates on
its business and clinical developments and news for its pipeline of
products.
To view the Company's Corporate Update Letter, please visit:
https://www.citiuspharma.com/wp-content/uploads/2020/10/CTXR_October-2020_Shareholder-Letter_final.pdf
About Citius Pharmaceuticals, Inc.
Citius is a
late-stage specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives and cancer care. For more information,
please visit www.citiuspharma.com.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "should," and
"may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results
to differ materially from those currently anticipated are: risks
associated with conducting clinical trials and drug development;
our dependence on third-party suppliers; our need for substantial
additional funds; patent and intellectual property matters; market
and other conditions; our ability to attract, integrate, and retain
key personnel; the estimated markets for our product candidates and
the acceptance thereof by any market; risks related to our growth
strategy; risks relating to the results of research and development
activities; uncertainties relating to preclinical and clinical
testing; the early stage of products under development; our ability
to obtain, perform under and maintain financing and strategic
agreements and relationships; our ability to identify, acquire,
close and integrate product candidates and companies successfully
and on a timely basis; government regulation; competition; as well
as other risks described in our SEC filings. We expressly disclaim
any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contact:
Andrew
Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-hc-wainwright-6th-annual-israel-conference-301168593.html
SOURCE Citius Pharmaceuticals, Inc.